Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tecalcet. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR known ✓ | P41180 | 13/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | HRH2 | P25021 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | HTR5A | P47898 | 1/20 | 1.00 |
| ▸ | HTR6 | P50406 | 1/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 1.00 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tecalcet SCHEMBL1178449 | 1.00 | CASR (1.00) | CASRHTR1AADRA2BADRA2CSLC6A2 | |
| Tecalcet SCHEMBL29374613 | 1.00 | CASR (1.00) | CASRHTR1AADRA2BADRA2CSLC6A2 | |
| Tecalcet SCHEMBL311950 | 0.99 | CASR (1.00) | CASRHTR1AADRA2BADRA2CSLC6A2 | |
| Tecalcet SCHEMBL1275509 | 0.99 | CASR (1.00) | CASRHTR1AADRA2BADRA2CSLC6A2 | |
| Tecalcet SCHEMBL31424064 | 0.99 | CASR (1.00) | CASRHTR1AADRA2BADRA2CSLC6A2 | |
| Tecalcet SCHEMBL30092843 | 0.99 | CASR (1.00) | CASRHTR1AADRA2BADRA2CSLC6A2 | |
| Tecalcet SCHEMBL896469 | 0.99 | CASR (1.00) | CASRHTR1AADRA2BADRA2CSLC6A2 | |
| Tecalcet SCHEMBL31424074 | 0.99 | CASR (1.00) | CASRHTR1AADRA2BADRA2CSLC6A2 | |
| SCHEMBL6222202 | 0.95 | CASR (0.93) | CASRHTR1AADRA2BADRA2CSLC6A2 | |
| SCHEMBL7355756 | 0.91 | CASR (0.84) | CASRHTR1AADRA2BADRA2CSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | claimed |
| EP-3110427-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | Urigen Pharmaceuticals, Inc. (US) | 2017-01-04 | — | — | EP | claimed |
| WO-2015127416-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | URIGEN PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | WO | claimed |
| JP-10168042-A | — | — | None | — | — | JP | disclosed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2023-04-20 | — | — | US | disclosed |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | ASCENDIS PHARMA A/S (DE) | 2023-01-24 | — | — | US | disclosed |
| EP-4011396-A1 | RELEASABLE CONJUGATES | QuiaPEG Pharmaceuticals AB (SE) | 2022-06-15 | — | — | EP | disclosed |
| EP-3592393-B1 | RELEASABLE CONJUGATES | QUIAPEG PHARMACEUTICALS AB (SE) | 2021-12-01 | — | — | EP | disclosed |
| US-20070060625-A1 | Methods of modulating intestinal fluid balance | AMGEN INC. (US) | 2007-03-15 | — | — | US | disclosed |
| WO-2007027548-A2 | METHODS OF MODULATING INTESTINAL FLUID BALANCE | AMGEN INC. (US) | 2007-03-08 | — | — | WO | disclosed |
| US-20060276534-A1 | Methods of decreasing calcification | AMGEN INC. (US) | 2006-12-07 | — | — | US | disclosed |
| WO-2006102061-A2 | METHODS OF DECREASING CALCIFICATION | AMGEN INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| JP-H10168042-A | PRODUCTION OF (R)-N-(ALPHA-METHYL-3-METHOXYBENZYL)-3-(2-CHLOROPHENYL)-1-PROPYLAMINE HYDROCHLORIDE | JIYUUKA FINE CHEM KK | 1998-06-23 | — | — | JP | disclosed |
| US-5648540-A | Amine preparation | NPS PHARMACEUTICALS, INC. (US) | 1997-07-15 | — | — | US | disclosed |
| US-5633404-A | N-((R)-α-methyl-3-methoxybenzyl)-3-(2-chlorobenzene)propanamide | NPS PHARMACEUTICALS, INC. (US) | 1997-05-27 | — | — | US | disclosed |
| US-5504253-A | Amine preparation | NPS PHARMACEUTICALS, INC. (US) | 1996-04-02 | — | — | US | disclosed |
| WO-1996002492-A1 | METHOD OF MAKING A BENZYLPROPANAMINE | NSP PHARMACEUTICALS, INC. (US) | 1996-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | CASR 2876/4885HTR1A 4232/4885ADRA2B 3726/4885 |
| US-20060276534-A1 | Methods of decreasing calcification | CALCB, CALCA, CALCR | CASR 9/4885HTR1A 4131/4885ADRA2B 1371/4885 |
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | CASR 2747/4885HTR1A 2677/4885ADRA2B 149/4885 |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | PLG, PHYKPL, PLOD3 | CASR 2876/4885HTR1A 4232/4885ADRA2B 3726/4885 |
| US-11786599-B2 | Releasable conjugates | GUSB, ABCB11, UGT2B7 | CASR 2747/4885HTR1A 2677/4885ADRA2B 149/4885 |
| US-20070060625-A1 | Methods of modulating intestinal fluid balance | SLC10A2, VIP, FABP2 | CASR 23/4885HTR1A 2979/4885ADRA2B 1484/4885 |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | SI, SLC20A1, SLC20A2 | CASR 2938/4885HTR1A 2488/4885ADRA2B 3377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.